⚖️ Weight Loss Peptides

A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.

Dose: 0.25–2.4 mg weekly (subcutaneous injection)

A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.

Dose: 2.5–15 mg weekly (subcutaneous injection)

A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.

Dose: 250–500 mcg daily (subcutaneous)

The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.

Dose: 0.6–3.0 mg daily (subcutaneous)

Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.

Dose: Trial range: 1–12 mg weekly (subcutaneous)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

Dose: Trial range: 0.16–4.5 mg weekly (subcutaneous)

A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.

Dose: Trial range: 0.6–6 mg weekly (subcutaneous)